|
|
Post by lennymnkd on Mar 27, 2023 19:37:24 GMT -5
Was thinking along those lines CAESAR , maybe she’s here for the transition…
|
|
|
|
Post by akemp3000 on Mar 27, 2023 21:46:27 GMT -5
Maybe the company hired an experienced person who they hope and expect will bring a lot to the table and do an excellent job...and that's all there is to this. As much fun as it is to speculate, it's probably best to keep expectations in check, at least until we hear some really big news.
|
|
|
|
Post by mymann on Mar 27, 2023 22:05:45 GMT -5
V-GO. Buy another company link to prior employee? Mike's collection of cheap companies to be diversified and the board gives him another raise.
|
|
|
|
Post by lennymnkd on Mar 28, 2023 3:10:24 GMT -5
Maybe the company hired an experienced person who they hope and expect will bring a lot to the table and do an excellent job...and that's all there is to this. As much fun as it is to speculate, it's probably best to keep expectations in check, at least until we hear some really big news. Acorda’s lead multiple sclerosis (MS) drug Ampyra is facing generic competition in the United States after it lost exclusivity in September 2018 including Mylan's MYL authorized generic version. During the first nine months of 2019, sales of Ampyra have tanked 68.7% year over year due to generic launches. Off patent drug ! Renewed with technosphere… on the cheap . like the Mann said “MAYBE WE WILL BUY THEM” pun intended 🤔 |
|
|
|
Post by Clement on Mar 28, 2023 6:32:40 GMT -5
It's 42 miles from Ardsley to Danbury.
|
|
|
|
Post by lennymnkd on Mar 28, 2023 7:35:09 GMT -5
Ardsley to Danbury?
|
|
|
|
Post by letitride on Mar 28, 2023 7:54:36 GMT -5
Looks like a move to put the right people in the right place.
|
|
|
|
Post by Clement on Mar 28, 2023 8:08:07 GMT -5
Acorda in Ardsley, NY (per Wikipedia. I see now that Yahoo Finance puts them in Pearl River, NY.)) Mannkind in Danbury, CT Does that qualify as a "next-door deal"? |
|
|
|
Post by hellodolly on Mar 28, 2023 9:44:58 GMT -5
Maybe the company hired an experienced person who they hope and expect will bring a lot to the table and do an excellent job...and that's all there is to this. As much fun as it is to speculate, it's probably best to keep expectations in check, at least until we hear some really big news. Acorda’s lead multiple sclerosis (MS) drug Ampyra is facing generic competition in the United States after it lost exclusivity in September 2018 including Mylan's MYL authorized generic version. During the first nine months of 2019, sales of Ampyra have tanked 68.7% year over year due to generic launches. Off patent drug ! Renewed with technosphere… on the cheap . like the Mann said “MAYBE WE WILL BUY THEM” pun intended 🤔 MC: "And we decided that our real focus is bringing our assets forward as fast as possible a decade to double down on new ideas within our platform or other platforms that we see out there and less so on trying to drive more partners." Mike sums it up in the following response on how they intend to go about achieving this, "There's a lot of companies out of money or refocusing their strategy and divesting noncore assets. And so, we'll keep looking, but we feel pretty good about where we stand and driving that future for value." As I said before and through my interpretation of MCs comments, they may have one of those molecules in a pipeline, stalled between trials due to the lack of cash, who will give it away early on (likely with some royalty agreement and cash up front) so Company-X can raise some non-dilutive funds.I also stated that in terms of opportunities for MNKD to go out and buy a molecule the timing is about right considering macro economic uncertainty for micro-cap biotechs. But we shouldn't connect the dots until we at least have had a bottle of wine. |
|
|
|
Post by longliner on Mar 28, 2023 11:06:35 GMT -5
Perhaps the hire was at the behest of Martine? She may have needed a specific skillset in place. There is plenty of activity on that front. It's an interesting time to be a MNKD shareholder. Not to belabor the point, the last diabetes company I had (PRVB), received quite a premium to the daily $6.70 to $25. I, of course, would expect a higher premium here.  |
|
|
|
Post by cretin11 on Mar 28, 2023 11:35:15 GMT -5
Q the theories on all platforms:
This hire is at the behest of Martine, it's a precursor to an announcement of new UTHR deal.
Huge deal with Boehringer for clofazamine is about to be announced, this hire is proof!
Boehringer is going to buy out MNKD at a massive premium, Sabella will be "the closer" (sorry Hooper).
MNKD is about to buy ACOR, a diamond in the rough waiting to shine.
Or just maybe, MNKD hired an experienced person who they hope will do a good job (credit to akemp for this boring but most-likely-to-be-true theory)!
|
|
|
|
Post by akemp3000 on Mar 28, 2023 11:47:24 GMT -5
There will surely be egg on our faces when all of this turns out to be true  |
|
|
|
Post by cretin11 on Mar 28, 2023 14:46:03 GMT -5
There will surely be egg on our faces when all of this turns out to be true I'd be delighted if even one of the four turn out to be true! Well, as long as it's not the fourth one there...  |
|
|
|
Post by runner on Mar 28, 2023 16:55:47 GMT -5
Maybe this is a prelude to moving the HQ to Danbury, and then ultimately a transition to a new CEO? Just a thought.
I hope we get news soon that there will be an in-person annual shareholders meeting.
|
|
|
|
Post by uvula on Mar 28, 2023 17:10:55 GMT -5
Is there a Speculators Anonymous group we can all join?
|
|
